Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Revenue (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Revenue for 16 consecutive years, with $47.7 million as the latest value for Q4 2025.

  • Quarterly Revenue fell 47.31% to $47.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $296.2 million through Dec 2025, down 15.72% year-over-year, with the annual reading at $296.2 million for FY2025, 15.72% down from the prior year.
  • Revenue hit $47.7 million in Q4 2025 for Ironwood Pharmaceuticals, down from $122.1 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $122.1 million in Q3 2025 to a low of $41.1 million in Q1 2025.
  • Historically, Revenue has averaged $95.7 million across 5 years, with a median of $100.6 million in 2021.
  • Biggest YoY gain for Revenue was 33.26% in 2025; the steepest drop was 47.31% in 2025.
  • Year by year, Revenue stood at $117.1 million in 2021, then fell by 8.48% to $107.2 million in 2022, then grew by 9.66% to $117.6 million in 2023, then dropped by 22.98% to $90.5 million in 2024, then crashed by 47.31% to $47.7 million in 2025.
  • Business Quant data shows Revenue for IRWD at $47.7 million in Q4 2025, $122.1 million in Q3 2025, and $85.2 million in Q2 2025.